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Summary High-dose etoposide (2.0-2.4 g m-2) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize
perpheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity. Sixty-three patients with
malignancy were enrolled into this non-randomized sequential study. The majority (55/63, 870,o) had received at least two prior regimens of
chemotherapy. and seven patients had previously failed to mobilize following high-dose cyclophosphamide with G-CSF. Consecutive patient
groups received etoposide at three dose levels [2.0 g m-2 (n = 22). 1.8 g m-2 (n = 20) and 1.6 g m-2 (n = 21)] followed by daily G-CSF.
Subsequent leukaphereses were assayed for CD34- cell content, with a target total collection of 2.0 x 106 CD34- cells kg-'. Toxicity was
assessed by the development of significant mucositis. the requirement for parenteral antibiotics or blood component support and
rehospitalization incidence. Ten patients (169o) had less than the minimum target yield collected. Median collections in the three groups were
4.7 (2 g m-2). 5.7 (1.8 g m-2) and 6.5 (1.6 g m-2) x 106 CD34- cells kg-'. Five of the seven patients who had previously failed cyclophosphamide
mobilization achieved more than the target yield. Rehospitalization incidence was significantly lower in patients receiving 1.6 g m-2 etoposide
than in those receiving 2.0 g m-2 (P = 0.03). These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in
the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF. An
etoposide dose of 1.6 g m-2 appears to be as effective as higher doses but less toxic.
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Currently. high-dose therapy with peripheral blood progenitor cell
(PBPC) support is increasinolv utilized in the treatment ofpatients
x ith haematological or non-haematolo2ical malianant disease.
The mobilization of sufficient numbers of these progenitor cells
from bone marrowx into the circulation for leukapheretic harvest
mav be achieved by either a haemopoietic growth factor [at
present usually granulocyte colony-stimulating-factor (G-CSF) or
granulocv-te-macrophage colony-stimulating factor (GNI-CSF)] or
cvtotoxic chemotherapy alone (Richman et al. 1976: To et al.
1990: Rosenfeld et al. 1996: Diaz Mediavilla et al. 1996 .
Howexer. the combination of cytotoxic chemotherapy w-ith a
2row-th factor may be more effective (Gianni et al. 1989:
Schwartzberg et al. 1992: Pettengell et al. 1993).
Tu-o prexious reports has-e indicated that high-dose etoposide
w-ith growxth factor may be employed for this purpose. Gianni et al
(1992) studied an etoposide dose of 2.0-2.4 2 m-' Awith G-CSF or
GNI-CSF. and in most patients minimal toxicity was experienced.
allo-Ming the regimen to be given as an outpatient procedure.
How-ever. none of these patients was heaxily pretreated. More
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recently. a study usingy etoposide at a dose of2.0 g mr- x`ith G-CSF
reported that nearly all patients. includingy those who had receix-ed
more than two prior chemotherapy regimens. mobilized PBPCs
successfully (Copelan et al. 1997). A proportion of these latter
patients dexeloped toxicity requiring hospitalization.
W'e have exaluated w-hether reducing the dose of etoposide
might lessen the toxicity experienced w-ithout significantly
affecting the effectiveness of the mobilization procedure. The
patient group studied was predominantly heavily pretreated and
included some that had previously failed to mobilize adequately
,-ith hioh-dose cyclophosphamide and G-CSF
PATIENTS AND METHODS
Between September 1994 and September 1997. 63 patients with
malignant disease w-ere enrolled into this non-randomized sequen-
tial studv. The first 22 patients received an etoposide dose of
2.0 m'. the next 20 patients a dose of 1.8 g m-' and the final 21
patients a dose of 1.6 g m-'. The total dose of undiluted etoposide
XMross et al. 1994) was gix-en on day I as a continuous intravenous
infusion via a central -ein over 10 h using a sxrin-e driver.
Patients w-ere hospitalized for the first 48 h of the mobilization
procedure. All patients receixved prophylactic antiemetic therapy.
acetazolamide '250 mg, orally ex en- 6 h for four doses) and
methylprednisolone (40 mg m-' intravenouslI even- 8 h for three
doses) peri-infusion (Gianni et al. 1992'. G-CSF 300 igc if body
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Table 1 Patient characteristics and resufts of mobilization
Etoposide dose CD34+ cells Number of
Patient Age, years (sex) Diagnosis Disease status (g m-2) colleted (x 10 kg-') leukaphereses
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54 (M)
22 (F)
31 (M)
25 (M)
17 (F)
28 (M)
60 (M)
45 (M)
30 (M)
23 (M)
26 (M)
42 (M)
27 (M)
35 (M)
36 (F)
53 (M)
51 (M)
39 (M)
44 (M)
41 (F)
41 (M)
46 (M)
27 (M)
52 (M)
32 (M)
32 (M)
26 (M)
28 (M)
28 (M)
23 (M)
34 (M)
26 (F)
29 (M)
52 (M)
49 (M)
26 (M)
44 (M)
55 (F)
70 (M)
31 (F)
43 (F)
47 (F)
16 (F)
36 (M)
46 (M)
27 (M)
34 (M)
24 (M)
36 (M)
19 (M)
30 (F)
42 (M)
16 (F)
65 (F)
48 (M)
44 (M)
44 (M)
32 (M)
42 (M)
32 (F)
67 (M)
54(F)
57 (F)
AML
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GCT
GCT
GCT
GCT
GCT
GCT
GCT
GCT
GCT
GCT
LYM-HD
LYM-HD
LYM-HD
LYM-NHL
LYM-NHL
LYM-NHL
LYM-NHL
LYM-NHL
LYM-NHL
MM
ALL
GCT
GCT
GCT
GCT
GCT
GCT
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GCT
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LYM-HD
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LYM-NHL
LYM-NHL
LYM-NHL
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LYM-NHL
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GCT
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GCT
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LYM-HD
LYM-HD
LYM-NHL
LYM-NHL
LYM-NHL
LYM-NHL
LYM-NHL
LYM-NHL
MM
MM
MM
CR2
Prim ref
Rel 1
CR3(+)
Rel 1
Prim ref
Rel 1
CR3(+)
Rel 1
Rel 1
Pnm ref
CR3(+)
CR3(+)
Rel 1
Rel 1
CR3(+)
Rel 2
CR3(+)
CR3(+)
Rel 1
Rel 1
Rel 2
CR1
Rel 2
CR3(+)
CR3(+)
CR2
CR3(+)
Rel 1
CR2
Rel 1
Rel 1
CR2
CR2
CR2
CR1
CR3(+)
Rel 1
CR2
CR1
Rel 1
CR3(+)
CR1
CR3 (+)
CR2
Rel 1
CR3(+)
CR1
Rel 1
Rel 1
CR2
Rel 2
CR1
CR3(+)
CR2
Prim ref
Rel 1
CR1
CR1
Rel 1
Pnm ref
Rel 1
Rel 1
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
2.0
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.8
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.6
1.4
5.2
3.4
5.9
5.8
4.1
3.7
3.0
27.1
13.9
26.1
3.6
3.4
17.2
11.5
0.0
9.9
5.8
0.3
12.0
2.6
2.9
3.5
11.2
5.1
60.1
27.6
40.8
15.2
6.0
6.4
27.9
2.6
8.4
2.4
5.3
4.1
2.0
16.0
2.2
2.0
1.9
3.1
14.6
14.1
20.5
18.1
4.9
2.3
19.9
2.5
6.5
24.2
2.4
14.3
21.0
25.5
0.0
26.6
0.2
0.0
37
0.1
2
2
2
2
2
1
1
2
1
1
3
2
1
1
2
1
2
2
4
2
1
1
1
1
1
12
1
2
4
13
1
1
1
2
1
1
1
1
1
1
2
1
2
1
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AML acute myeloid leukaemia: ChC. chonrocanorna; GCT. germ-cell tumour LYM-HD. Hodgkin's disease: LYM-NHL. non Hodgkin'stymphoma: MM.
myek)rna; ALL acute lymphoblasbc leukaemia; CR1. first remission; CR2. second remission; Prim ref. primary refractory disease: Rel 1. first relapse: Rel 2.
second relapse: CR3(+). third remission or more advanced disease.
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weight < 70 kg. 480 zgg if > 70 krg) was started on day 3 and gis en
daily subcutaneously until leukapheresis was completed. Patients
Were discharged from hospital on day 3. taking prophylactic
ciprofloxacin (500 mg ts-ice daily). Toxicity of the mobilization
procedure s-as assessed by the deselopment of significant (WHO
grade 2-4) oropharyngeal mucositis. the requirement for blood
or platelet transfusions. the deselopment of sepsis necessitating
parenteral antibiotic therapy and the rehospitalization incidence.
Leukapheresis s as commenced shen the preceding day s circu-
lating CD34- cell concentration predicted that an adequate collec-
tion would be obtained the followving day. as previously described
(Elliott et al. 1996). Assays for circulating CD34- cell concentra-
tions were initiated from the twelfth day following etoposide
administration. All collections wvere har ested using a Cobe
Spectra (Cobe Laboratories. Quedgeley. UK.) Asith a target
processing of 2.5 times the estimated patient blood s-olume. If an
insufficient CD34- sield resulted from the first leukapheresis
further collections Aere obtained on subsequent days.
CD34- concentrations in both blood samples and leukapheretic
products were measured flosw cytometrically by dual staining for
CD45 and CD34. The CD45- cell population wsas cated and then
anal-sed for the percentage of CD34- cells (Sutherland et al.
1994). The CD34- concentration wsas derived bv reference to the
white cell count of the sample.
RESULTS
Patient characteristics
Patient characteristics are shosn in Table 1. Thirts-one (49%c) of
the 63 patients had lymphoma [Hodgkin's disease (HD) or non-
Hodgkin's lymphoma (NHL)]. 24 (38%7c) germ cell tumour (GCT)
and the remaining eight patients (13%) had myeloma (n = 4). acute
leukaemia (n = 3) or choriocarcinoma (n = 1). All patients w-ith
lImphoma had receised first-line therapy with either BEMOP-CA
(bleomycin. etoposide. methotrexate. sincristine. prednisolone.
cyclophosphamide. doxorubicin) or CHOP (cyclophosphamide.
doxorubicin. vincristine. prednisolone). and second-line therapy w-ith
MOPP (mustine. vincristine. procarbazine. prednisolone) ifrelapsed
HD or DHAP (dexamethasone. cytosine arabinoside. cisplatinum) if
relapsed NHL. All patients swith GCT had recei ed first-line
therapy w-ith POMB-ACE (cisplatinum. sincristine. methotrexate.
bleomycin. actinomycin. etoposide. cyclophosphamide). and second-
line therapy with an alternating cisplatinum/taxol-etoposide/taxol
schedule. The patients swith myeloma had receis ed as a minimum
melphalan and/or VAD therapx (vincrstine. doxorubicin. dexa-
methasone). Forty-ses en patients (75%) s-ere male. and patient age
ranged from 16 to 70 years (median 36). Fiftv-five patients (87%)
had disease beyond first remission and had received tvo or more
chemotherapv regimens before the mobilization procedure. Seven
patients (four with myeloma. two with lymphoma and one with
acute leukaemia) had previously failed mobilization therapy w-ith
cyclophosphamide (2-4 g mr ) and G-CSF. based on actual yields
obtained and also on peak blood CD34- concentrations of less than
6 x IW 1- (Elliott et al. 1996).
Toxicity
Significant oropharyngeal mucositis requiring opiate analgesia
de eloped in four (6%) patients follosing etoposide. This compli-
cation was sufficiently severe in three patients to necessitate hospi-
talization. In total. 23 patients (37%7) were readmitted to hospital
during the mobilization procedure. In 20 (32%7 ) cases this s as due
to sepsis requiring parenteral antibiotic therapy. Haematological
toxicity requiring support with blood or platelet transfusion
developed in 28 (44%) patients. There were no procedure-related
mortalities observed in this study.
The incidences ofthese toxicities and rehospitalization appeared
to be lowest in the group ofpatients who received 1.6 ga m-2 etopo-
side (Table 2). In particular. 4 of these 21 (19% ) patients required
readmission to hospital compared with 8 of20 (40%) and 11 of 22
(50%) patients in the 1.8 g mr2 and 2.0 ga m- groups respectivelv.
Howeser. only the comparison between rehospitalization inci-
dence in the 1.6 g mr2 and 2.0 g m-' groups reached statistical
significance (P = 0.03. tu-o-tailed chi-square test): all other
comparisons sere non-significant.
Leukaphereses and PBPC yields
The number of leukaphereses performed and the CD34 cells
collected are shown in Table 1. The first day ofleukapheresis in these
63 patients vwas at a median of 13 days follosing etoposide therapy
(range 12-19 days). and was not different in the three groups of
etoposide dosage (data not shown). Three patients (1 in the 2.0 g mrn
and two in the 1.6 g m- etoposide groups) failed to mobilize (as indi-
cated by the peripheral blood CD34- concentration) and were not
leukapheresed. A further seven patients (two each in the 2.0 g mrn
and 1.6 gm- groups. three in the 1.8 gm- group) failed to achieve
total sields of 2.0 x I0W CD-34 cells kg-. Mobilization procedures
that produced yields ofgreater than this target number wereachieved
in 53 (84%) patients. The median numberofCD34+ cells collected in
all 63 patients was 5.3 x l0YkgQ'in an a erage of 1.5 leukaphereses
(Table 3). Median yields (x lW CD-34 cells kE-w¼ in the three
etoposide dosage groups sere 4.7 (2.0 m-n'. 5.7 (1.8 mr-) and
Table 2 Toxicity
Etoposide dose (g m-2)
2.0 1.8 1.6 Total
Toxicity [no. of patients>(%)] (n = 22) (n = 20) (n = 21) (n = 63)
Grade 2-4 (WHO) mucositis 3 (14°o) 1 (501o) 0 (0°o) 4 (6°o)
Blood orplatelettransfusion 11 (50%o) 10(500o) 7(330°o) 28(44%o)
Parenteral antibiotics 10 (45%) 6 (30%'o) 4 (199%) 20 (320,o)
Hospitalizationa 11 (50%) 8 (40%.o) 4 (19%o) 23 (370o)
a1.6 g m- vs 2.0 gm-r. P = 0.03. All other comparisons non-significant.
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Table 3 PBPC yields
Etoposide dose (g m-2)
2.0 1.8 1.6 All patients
(n = 22) (n = 20) (n = 21) (n = 63)
CD34- cells (median) x 1O( kg-' collected (range) 4.7 (0.0-27.1) 5.7 (1.9-60.1) 6.5 (0.0-26.6) 5.3 (0.0-60.1)
Number (median) of leukaphereses (range) 2 (0-4)- 1 (1-4) 1 (0-4): 1 (0-4)
alncluding one patient who was not leukapheresed. Including two patients who were not leukapheresed.
Table 4 Etoposide/G-CSF mobilization in patients previously failing cyclophosphamideWG-CSF
CyckophosphamkdeG-CSF EtoposkeGCSF
Diagnosisa (x 106 CD34, cells/kg-') (x 10 CD34+ cells kg-') Etoposide dose (g rn-2) Number of leukaphereses
LYM-NHL 0.3 5.8 2.0 2
MM 0.1 2.9 2.0 4
LYM-NHL 1.4 2.6 2.0 2
ALL 0.0 3.5 1.8 2
MM 0.1 0.0 1.6 0
MM 0.0 0.1 1.6 1
MM 1.1 3.7 1.6 2
aFor abbreviations see Table 1.
6.5 (1.6 g m- ) and the axerage number of leukaphereses required
were 1.7(2.0Om- 41.30.8gm-')and 1.50.6gm-4).
Fixe of the sexen patients w-ho had previously failed cyclo-
phosphamide x-ith G-CSF mobilization achieved the target yield
following etoposide/G-CSF (Table 4). The two patients in this
group wxho did not mobilize successfully follow-ing etoposide/G-
CSF had an underlyinc diagnosis of myeloma and both receixed
1.6 g m- etoposide.
DISCUSSION
Sexeral studies have suggested that the use of PBPCs to support
high-dose therapy has advantages compared with autologous
bone marrow (Elias et al. 1992: To et al. 1992: Chao et al. 1993:
Schmitz et al. 1996). These benefits mav include shorter median
duration of neutropenia and thrombocv-topenia. fewxer febrile
episodes with reduced antibiotic requirement. shorter hospitaliza-
tion and lowxer procedural costs.
The procurement ofPBPCs for this purpose has most often been
accomplished using a combination of cvclophosphamide w-ith
G-CSF. but not all patients mobilize successfully. In particular.
leukapheretic yields may be suboptimal in patients who have
received several preceding regimens ofchemotherapy (Haas et al.
1994: Dreger et al. 1995). Strategies employed to improxe the
results of mobilization haxe included increasing the dose of
cyclophosphamide administered or using combinations of cyto-
toxic drugs (Lie et al. 1996: Dernirer et al. 1997: McQuaker et al.
1997). The majoritx of patients (87%7c) in the present study had
receixed at least two prior schedules of chemotherapy. and the
mobilization therapy was successful in 53 of63 patients (84%7c). In
addition. fixve of sex en patients w-ho had prex iously failed to
achieve a target collection of 2.0 x I0 CD34- cells kg-'I with
cxclophosphamide/G-CSF mobilization x ielded an adequate
harvest following etoposide/G-CSF. These data confirm that high-
dose etoposide with G-CSF is an effectix e mobilization regimen in
the majority of patients. despite substantial prex ious therapy or an
initial failure to mobilize PBPCs with cyclophosphamide/G-CSF.
The percentage of patients who mobilized PBPCs adequately
and the median number of CD34- cells kg-1 obtained were not
different between the three groups of etoposide dosage. In
contrast. the toxicity experienced wvas lowest in those who
received 1.6 g m- . with only 4 of these 21 patients needing re-
admission to hospital. In general. however. the toxic complications
and rehospitalization frequency appear to haxe been greater than
in the two previous reports of high-dose etoposide with G-
CSF/GM-CSF. In the first study none ofthe patients ex aluated had
been heaxily pretreated (Gianni et al. 1992). and in the second
approximatelv 50%7 of the patients studied had breast cancer
(Copelan et al. 1997). In a separate study at this centre PBPCs
have been collected from more than 50 patients with high-risk
primary breast cancer follox-ing mobilization with combination
chemotherapy and G-CSF. and in none ofthese has readmission to
hospital been required. suggesting that both prexious therapy and
underlyinc diagnosis may impact on procedural complications.
The equixalent cell yields in the three groups of etoposide
dosage may sugaest that a further reduction miaht eliminate
toxicity without impairinc PBPC mobilization. Howexer. although
disease response x as not specifically exaluated in this study. there
is evidence that high-dose etoposide is an effectixe agent in a
varietv of tumours (Postmus et al. 1984: Marangolo et al. 1989:
Herzig. 1991: Bezwoda et al. 1992). It may therefore be adxanta-
geous to employ an etoposide dose sufficient to exploit this poten-
tial anti-tumour activitv. These data indicate that 1.6 m-' may
represent a reasonable compromise for this purpose. enabling the
successful mobilization of adequate PBPCs for the support of
subsequent high-dose therapy but uith acceptable toxicitx.
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